Blau J, Xiao H, McCracken S, O'Hare P, Greenblatt J, Bentley D
Molecular Genetics of Differentiation Laboratory, Imperial Cancer Research Fund, London, UK.
Mol Cell Biol. 1996 May;16(5):2044-55. doi: 10.1128/MCB.16.5.2044.
We have studied the abilities of different transactivation domains to stimulate the initiation and elongation (postinitiation) steps of RNA polymerase II transcription in vivo. Nuclear run-on and RNase protection analyses revealed three classes of activation domains: Sp1 and CTF stimulated initiation (type I); human immunodeficiency virus type 1 Tat fused to a DNA binding domain stimulated predominantly elongation (type IIA); and VP16, p53, and E2F1 stimulated both initiation and elongation (type IIB). A quadruple point mutation of VP16 converted it from a type IIB to a type I activator. Type I and type IIA activators synergized with one another but not with type IIB activators. This observation implies that synergy can result from the concerted action of factors stimulating two different steps in transcription: initiation and elongation. The functional differences between activators may be explained by the different contacts they make with general transcription factors. In support of this idea, we found a correlation between the abilities of activators, including Tat, to stimulate elongation and their abilities to bind TFIIH.
我们研究了不同反式激活结构域在体内刺激RNA聚合酶II转录起始和延伸(起始后)步骤的能力。核延伸和核糖核酸酶保护分析揭示了三类激活结构域:Sp1和CTF刺激起始(I型);与DNA结合结构域融合的人类免疫缺陷病毒1型Tat主要刺激延伸(IIA型);VP16、p53和E2F1刺激起始和延伸(IIB型)。VP16的四点突变使其从IIB型转变为I型激活剂。I型和IIA型激活剂相互协同作用,但与IIB型激活剂不协同。这一观察结果表明,协同作用可能源于刺激转录中两个不同步骤(起始和延伸)的因子的协同作用。激活剂之间的功能差异可能由它们与一般转录因子的不同接触来解释。为支持这一观点,我们发现包括Tat在内的激活剂刺激延伸的能力与其结合TFIIH的能力之间存在相关性。